# Serina Therapeutics, Inc. (SER) · Edgar & Edgarette company card

> Serina Therapeutics (SER) grew revenue 132% in FY2025 to $0 million, operating margin -18478% against a -3.8% median for pharmaceutical preparations, equity -0.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1708599 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SER) · [JSON](https://www.pops4.com/boards/company/SER.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $130,000 |
| Revenue growth, 1 year | 132.1% |
| Revenue growth per year | -2.5% |
| Operating margin | -18478.5% (prior year -30442.9%) |
| Net margin | -14780.8% |
| Operating cash flow | −$18M |
| Capital spending | $59,000 |
| Free cash flow | −$18M |
| Cash | $3M |
| Long-term debt | — |
| Total assets | $7M |
| Total equity | −$37,000 |
| Equity ÷ assets | -0.5% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -50.64 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$18.0M in FY2025); operating loss: a margin of -18478.5% in FY2025; revenue is hard to predict: its 80% range is ±87%

## Edgarette's reading

Exposure: revenue $130K (FY2025). Experience: revenue up 132.1% on the year, down 2.5% a year over 4 years; operating margin -18478.5%, up from -30442.9%. Soundness: equity -0.5% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $67K and $937K next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $56K to $1.1M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -18478.5% against a -3.8% median; growth 132.1% against 13.7%.

Range logged 2026-10-12, receipt 21a2b65cd35be45c, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-01-15 ([filing](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000003/0001708599-26-000003-index.htm))
- Item 5.02 Director or officer change: 4, latest 2026-07-23 ([filing](https://www.sec.gov/Archives/edgar/data/1708599/000162828026049426/0001628280-26-049426-index.htm))

## Recent filings

- 8-K · filed 2026-11-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000069/0001708599-26-000069-index.htm)
- 10-Q · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000068/0001708599-26-000068-index.htm)
- 8-K · filed 2026-10-09 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000060/0001708599-26-000060-index.htm)
- 8-K · filed 2026-09-09 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000054/0001708599-26-000054-index.htm)
- 8-K · filed 2026-08-27 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000051/0001708599-26-000051-index.htm)
- S-1 · filed 2026-08-24 · [filing](https://www.sec.gov/Archives/edgar/data/1708599/000149315226039910/0001493152-26-039910-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001708599.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1708599

## Cite

POPS4, Edgar & Edgarette: Serina Therapeutics, Inc. (SER) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/SER. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

